AFFiRiS is a clinical-stage biopharmaceutical company that pursues the ultimate aim to improve the lives of patients suffering from neurodegenerative diseases by providing disease-modifying specific active immunotherapies (SAIT) based on its proprietary patented AFFITOME® technology.
We strive to deliver much‑needed therapies to patients with debilitating and life‑threatening neurodegenerative diseases, such as Parkinson’s disease, multiple system atrophy (MSA), dementia with Lewy Bodies (DLB), and Huntington’s disease.
We aim to surpass currently available treatments.
RECENT PRESS RELEASES
18 June 2020
The Lancet Neurology publishes positive results of AFFiRiS’ Phase 1 trial with PD01A in Parkinson’s disease patients
27 July 2021
AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases
27 May 2021
Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology
10 September 2020
AFFiRiS announces publication in Movement Disorders Journal of positive clinical results of a Phase 1 trial in early Multiple System Atrophy
11 September 2020
AFFiRiS announces late-breaking presentation of clinical PD01 data in Parkinson’s disease patients at the MDS Virtual Congress
WHERE TO MEET US
12-16 September 2020
International Conference on Parkinsons and Movement Disorders (Virtual)
5-6 October 2020
HealthTech Innovation Days
Paris, France and Virtual
11-12 May 2020
The Neuro4D Conference 2020
Specific Active ImmunoTherapy (SAIT)
Adherence to current therapies can be poor due to complex dosing regimens, and the treatment of many neurodegenerative diseases is stillinadequate. Using our unique AFFITOME technology, we are developing Specific Active ImmunoTherapy (SAIT), which stimulates the body to find and fight proteins central to the development and progression of neurodegenerative diseases. SAIT induces a long‑lasting target-specific immune response, which may be generated by far less frequent dosing regimens (e.g. once or twice a year)
SAIT is an exciting prospect.
We focus on identifying proteins that are involved in the development and progression of neurodegenerative diseases, and establishing novel SAIT treatments against pathogenic forms of these proteins using our unique AFFITOME technology. SAIT has successfully demonstrated proof of concept in both preclinical and clinical studies. Our most advanced product candidates are entering Phase II clinical trials.
We are moving forward.